Medicine (Austin & Northern Health) - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 7 of 7
  • Item
    Thumbnail Image
    Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy
    Bagnall, RD ; Crompton, DE ; Petrovski, S ; Lam, L ; Cutmore, C ; Garry, SI ; Sadleir, LG ; Dibbens, LM ; Cairns, A ; Kivity, S ; Afawi, Z ; Regan, BM ; Duflou, J ; Berkovic, SF ; Scheffer, IE ; Semsarian, C (WILEY, 2016-04)
    OBJECTIVE: The leading cause of epilepsy-related premature mortality is sudden unexpected death in epilepsy (SUDEP). The cause of SUDEP remains unknown. To search for genetic risk factors in SUDEP cases, we performed an exome-based analysis of rare variants. METHODS: Demographic and clinical information of 61 SUDEP cases were collected. Exome sequencing and rare variant collapsing analysis with 2,936 control exomes were performed to test for genes enriched with damaging variants. Additionally, cardiac arrhythmia, respiratory control, and epilepsy genes were screened for variants with frequency of <0.1% and predicted to be pathogenic with multiple in silico tools. RESULTS: The 61 SUDEP cases were categorized as definite SUDEP (n = 54), probable SUDEP (n = 5), and definite SUDEP plus (n = 2). We identified de novo mutations, previously reported pathogenic mutations, or candidate pathogenic variants in 28 of 61 (46%) cases. Four SUDEP cases (7%) had mutations in common genes responsible for the cardiac arrhythmia disease, long QT syndrome (LQTS). Nine cases (15%) had candidate pathogenic variants in dominant cardiac arrhythmia genes. Fifteen cases (25%) had mutations or candidate pathogenic variants in dominant epilepsy genes. No gene reached genome-wide significance with rare variant collapsing analysis; however, DEPDC5 (p = 0.00015) and KCNH2 (p = 0.0037) were among the top 30 genes, genome-wide. INTERPRETATION: A sizeable proportion of SUDEP cases have clinically relevant mutations in cardiac arrhythmia and epilepsy genes. In cases with an LQTS gene mutation, SUDEP may occur as a result of a predictable and preventable cause. Understanding the genetic basis of SUDEP may inform cascade testing of at-risk family members.
  • Item
    Thumbnail Image
    Quantitative analysis of phenotypic elements augments traditional electroclinical classification of common familial epilepsies
    Abou-Khalil, B ; Afawi, Z ; Allen, AS ; Bautista, JF ; Bellows, ST ; Berkovic, SF ; Bluvstein, J ; Burgess, R ; Cascino, G ; Cossette, P ; Cristofaro, S ; Crompton, DE ; Delanty, N ; Devinsky, O ; Dlugos, D ; Ellis, CA ; Epstein, MP ; Fountain, NB ; Freyer, C ; Geller, EB ; Glauser, T ; Glynn, S ; Goldberg-Stern, H ; Goldstein, DB ; Gravel, M ; Haas, K ; Haut, S ; Heinzen, EL ; Kirsch, HE ; Kivity, S ; Knowlton, R ; Korczyn, AD ; Kossoff, E ; Kuzniecky, R ; Loeb, R ; Lowenstein, DH ; Marson, AG ; McCormack, M ; McKenna, K ; Mefford, HC ; Motika, P ; Mullen, SA ; O'Brien, TJ ; Ottman, R ; Paolicchi, J ; Parent, JM ; Paterson, S ; Petrou, S ; Petrovski, S ; Pickrell, WO ; Poduri, A ; Rees, MI ; Sadleir, LG ; Scheffer, IE ; Shih, J ; Singh, R ; Sirven, J ; Smith, M ; Smith, PEM ; Thio, LL ; Thomas, RH ; Venkat, A ; Vining, E ; Von Allmen, G ; Weisenberg, J ; Widdess-Walsh, P ; Winawer, MR (WILEY, 2019-11)
    OBJECTIVE: Classification of epilepsy into types and subtypes is important for both clinical care and research into underlying disease mechanisms. A quantitative, data-driven approach may augment traditional electroclinical classification and shed new light on existing classification frameworks. METHODS: We used latent class analysis, a statistical method that assigns subjects into groups called latent classes based on phenotypic elements, to classify individuals with common familial epilepsies from the Epi4K Multiplex Families study. Phenotypic elements included seizure types, seizure symptoms, and other elements of the medical history. We compared class assignments to traditional electroclinical classifications and assessed familial aggregation of latent classes. RESULTS: A total of 1120 subjects with epilepsy were assigned to five latent classes. Classes 1 and 2 contained subjects with generalized epilepsy, largely reflecting the distinction between absence epilepsies and younger onset (class 1) versus myoclonic epilepsies and older onset (class 2). Classes 3 and 4 contained subjects with focal epilepsies, and in contrast to classes 1 and 2, these did not adhere as closely to clinically defined focal epilepsy subtypes. Class 5 contained nearly all subjects with febrile seizures plus or unknown epilepsy type, as well as a few subjects with generalized epilepsy and a few with focal epilepsy. Family concordance of latent classes was similar to or greater than concordance of clinically defined epilepsy types. SIGNIFICANCE: Quantitative classification of epilepsy has the potential to augment traditional electroclinical classification by (1) combining some syndromes into a single class, (2) splitting some syndromes into different classes, (3) helping to classify subjects who could not be classified clinically, and (4) defining the boundaries of clinically defined classifications. This approach can guide future research, including molecular genetic studies, by identifying homogeneous sets of individuals that may share underlying disease mechanisms.
  • Item
    Thumbnail Image
    Epileptic spasms are a feature of DEPDC5 mTORopathy
    Carvill, GL ; Crompton, DE ; Regan, BM ; McMahon, JM ; Saykally, J ; Zemel, M ; Schneider, AL ; Dibbens, L ; Howell, KB ; Mandelstam, S ; Leventer, RJ ; Harvey, AS ; Mullen, SA ; Berkovic, SF ; Sullivan, J ; Scheffer, IE ; Mefford, HC (LIPPINCOTT WILLIAMS & WILKINS, 2015-08)
    OBJECTIVE: To assess the presence of DEPDC5 mutations in a cohort of patients with epileptic spasms. METHODS: We performed DEPDC5 resequencing in 130 patients with spasms, segregation analysis of variants of interest, and detailed clinical assessment of patients with possibly and likely pathogenic variants. RESULTS: We identified 3 patients with variants in DEPDC5 in the cohort of 130 patients with spasms. We also describe 3 additional patients with DEPDC5 alterations and epileptic spasms: 2 from a previously described family and a third ascertained by clinical testing. Overall, we describe 6 patients from 5 families with spasms and DEPDC5 variants; 2 arose de novo and 3 were familial. Two individuals had focal cortical dysplasia. Clinical outcome was highly variable. CONCLUSIONS: While recent molecular findings in epileptic spasms emphasize the contribution of de novo mutations, we highlight the relevance of inherited mutations in the setting of a family history of focal epilepsies. We also illustrate the utility of clinical diagnostic testing and detailed phenotypic evaluation in characterizing the constellation of phenotypes associated with DEPDC5 alterations. We expand this phenotypic spectrum to include epileptic spasms, aligning DEPDC5 epilepsies more with the recognized features of other mTORopathies.
  • Item
    Thumbnail Image
    Intronic ATTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2
    Corbett, MA ; Kroes, T ; Veneziano, L ; Bennett, MF ; Florian, R ; Schneider, AL ; Coppola, A ; Licchetta, L ; Franceschetti, S ; Suppa, A ; Wenger, A ; Mei, D ; Pendziwiat, M ; Kaya, S ; Delledonne, M ; Straussberg, R ; Xumerle, L ; Regan, B ; Crompton, D ; van Rootselaar, A-F ; Correll, A ; Catford, R ; Bisulli, F ; Chakraborty, S ; Baldassari, S ; Tinuper, P ; Barton, K ; Carswell, S ; Smith, M ; Berardelli, A ; Carroll, R ; Gardner, A ; Friend, KL ; Blatt, I ; Iacomino, M ; Di Bonaventura, C ; Striano, S ; Buratti, J ; Keren, B ; Nava, C ; Forlani, S ; Rudolf, G ; Hirsch, E ; Leguern, E ; Labauge, P ; Balestrini, S ; Sander, JW ; Afawi, Z ; Helbig, I ; Ishiura, H ; Tsuji, S ; Sisodiya, SM ; Casari, G ; Sadleir, LG ; van Coller, R ; Tijssen, MAJ ; Klein, KM ; van den Maagdenberg, AMJM ; Zara, F ; Guerrini, R ; Berkovic, SF ; Pippucci, T ; Canafoglia, L ; Bahlo, M ; Striano, P ; Scheffer, IE ; Brancati, F ; Depienne, C ; Gecz, J (NATURE PUBLISHING GROUP, 2019-10-29)
    Familial Adult Myoclonic Epilepsy (FAME) is characterised by cortical myoclonic tremor usually from the second decade of life and overt myoclonic or generalised tonic-clonic seizures. Four independent loci have been implicated in FAME on chromosomes (chr) 2, 3, 5 and 8. Using whole genome sequencing and repeat primed PCR, we provide evidence that chr2-linked FAME (FAME2) is caused by an expansion of an ATTTC pentamer within the first intron of STARD7. The ATTTC expansions segregate in 158/158 individuals typically affected by FAME from 22 pedigrees including 16 previously reported families recruited worldwide. RNA sequencing from patient derived fibroblasts shows no accumulation of the AUUUU or AUUUC repeat sequences and STARD7 gene expression is not affected. These data, in combination with other genes bearing similar mutations that have been implicated in FAME, suggest ATTTC expansions may cause this disorder, irrespective of the genomic locus involved.
  • Item
    No Preview Available
    Familial Mesial Temporal Lobe Epilepsy and the Borderland of Deja Vu
    Perucca, P ; Crompton, DE ; Bellows, ST ; McIntosh, AM ; Kalincik, T ; Newton, MR ; Vajda, FJE ; Scheffer, IE ; Kwan, P ; O'Brien, TJ ; Tan, KM ; Berkovic, SF (WILEY, 2017-08)
    OBJECTIVE: The cause of mesial temporal lobe epilepsy (MTLE) is often unknown. We ascertained to what extent newly diagnosed nonlesional MTLE actually represents familial MTLE (FMTLE). METHODS: We identified all consecutive patients presenting to the Austin Health First Seizure Clinic with MTLE and normal magnetic resonance imaging (MRI) or MRI evidence of hippocampal sclerosis over a 10-year period. Patients' first-degree relatives and pairwise age- and sex-matched controls underwent a comprehensive epilepsy interview. Each interview transcript was reviewed independently by 2 epileptologists, blinded to relative or control status. Reviewers classified each subject as follows: epilepsy, specifying if MTLE; manifestations suspicious for epilepsy; or unaffected. Physiological déjà vu was noted. RESULTS: Forty-four patients were included. At the Clinic, MTLE had been recognized to be familial in 2 patients only. Among 242 subjects interviewed, MTLE was diagnosed in 9 of 121 relatives versus 0 of 121 controls (p = 0.008). All affected relatives had seizures with intense déjà vu and accompanying features; 6 relatives had not been previously diagnosed. Déjà vu experiences that were suspicious, but not diagnostic, of MTLE occurred in 6 additional relatives versus none of the controls (p = 0.04). Physiological déjà vu was common, and did not differ significantly between relatives and controls. After completing the relatives' interviews, FMTLE was diagnosed in 8 of 44 patients (18.2%). INTERPRETATION: FMTLE accounts for almost one-fifth of newly diagnosed nonlesional MTLE, and it is largely unrecognized without direct questioning of relatives. Relatives of patients with MTLE may experience déjà vu phenomena that clinically lie in the "borderland" between epileptic seizures and physiological déjà vu. Ann Neurol 2017;82:166-176.
  • Item
    Thumbnail Image
    Mutations in Mammalian Target of Rapamycin Regulator DEPDC5 Cause Focal Epilepsy with Brain Malformations
    Scheffer, IE ; Heron, SE ; Regan, BM ; Mandelstam, S ; Crompton, DE ; Hodgson, BL ; Licchetta, L ; Provini, F ; Bisulli, F ; Vadlamudi, L ; Gecz, J ; Connelly, A ; Tinuper, P ; Ricos, MG ; Berkovic, SF ; Dibbens, LM (WILEY-BLACKWELL, 2014-05)
    We recently identified DEPDC5 as the gene for familial focal epilepsy with variable foci and found mutations in >10% of small families with nonlesional focal epilepsy. Here we show that DEPDC5 mutations are associated with both lesional and nonlesional epilepsies, even within the same family. DEPDC5-associated malformations include bottom-of-the-sulcus dysplasia (3 members from 2 families), and focal band heterotopia (1 individual). DEPDC5 negatively regulates the mammalian target of rapamycin (mTOR) pathway, which plays a key role in cell growth. The clinicoradiological phenotypes associated with DEPDC5 mutations share features with the archetypal mTORopathy, tuberous sclerosis, raising the possibility of therapies targeted to this pathway.
  • Item
    No Preview Available
    Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency
    Arsov, T ; Mullen, SA ; Damiano, JA ; Lawrence, KM ; Huh, LL ; Nolan, M ; Young, H ; Thouin, A ; Dahl, H-HM ; Berkovic, SF ; Crompton, DE ; Sadleir, LG ; Scheffer, IE (WILEY-BLACKWELL, 2012-12)
    Glucose transporter 1 (GLUT1) deficiency caused by mutations of SLC2A1 is an increasingly recognized cause of genetic generalized epilepsy. We previously reported that >10% (4 of 34) of a cohort with early onset absence epilepsy (EOAE) had GLUT1 deficiency. This study uses a new cohort of 55 patients with EOAE to confirm that finding. Patients with typical absence seizures beginning before 4 years of age were screened for solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1) mutations or deletions. All had generalized spike-waves on electroencephalography (EEG). Those with tonic and/or atonic seizures were excluded. Mutations were found in 7 (13%) of 55 cases, including five missense mutations, an in-frame deletion leading to loss of a single amino acid, and a deletion spanning two exons. Over both studies, 11 (12%) of 89 probands with EOAE have GLUT1 deficiency. Given the major treatment and genetic counseling implications, this study confirms that SLC2A1 mutational analysis should be strongly considered in EOAE.